-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option --

ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, within UNC Health OB/GYN practice locations.